Atovaquone/proguanil for the prophylaxis and treatment of malaria

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 6, 2005, Pages 849-861

  Patel, Samir N ^a   Kain, Kevin C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atovaquone; Cytochrome b; Drug resitance; Malaria; Pharmacokinetics; Plasmodium falciparum; Plasmodium vivax; Proguanil; Prophylaxis

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; CYCLOGUANIL; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; METOCLOPRAMIDE; PLACEBO; PRIMAQUINE; PROGUANIL; QUININE; RIFABUTIN; RIFAMPICIN; TAFENOQUINE; TETRACYCLINE; ZIDOVUDINE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CLINICAL TRIAL; CONGENITAL MALFORMATION; COUGHING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENDEMIC DISEASE; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; MALARIA; MENTAL DISEASE; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POSTMARKETING SURVEILLANCE; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMACH PAIN; TRAVEL; TREATMENT FAILURE; VOMITING;

ANIMALS; ATOVAQUONE; CHLOROGUANIDE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; NAPHTHOQUINONES;

EID: 28944445871     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.6.849     Document Type: Review

References (76)

1. Snow R, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 10(434), 214-217 (2005).
2. Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 164(5), 654-659 (2001).
3. Suh KN, Kain KC, Keystone JS. Malaria. CMAJ 170(11), 1693-1702 (2004).
4. Muentener P, Schlagenhauf P, Steffen R. Imported malaria (1985-95): trends and perspectives. Bull. World Health Organ. 77(7), 560-566 (1999).
5. Baird JK. Effectiveness of antimalarial drugs. N. Engl. J. Med. 352(15), 1565-1577 (2005).
6. Newman RD, Parise ME, Barber AM, Steketee RW. Malaria related deaths among US travelers, 1963-2001. Ann. Intern. Med. 141(7), 547-555 (2004).
7. Eliades MJ, Shah S, Nguyen-dinh P et al. Malaria surveillance - United States, 2003. MMWR Surveill. Summ. 4(2), 25-40 (2005).
8. Lell B, Faucher JF, Missinou MA et al. Malaria chemoprophylaxis with tafenoquine: a randomized study. Lancet 355(9220), 2041-2045 (2000).
9. Shanks GD, Oloo AJ, Aleman GM et al. A new primaquine analogue, tafenoquine (WR 239605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis. 33(12), 1968-1974 (2001).
10. Hale BR, Owusu-Agyei S, Fryauff DJ et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin. Infect. Dis. 36(5), 541-549 (2003).
11. Walsh DS, Wilairatana P, Tang DB et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin. Infect. Dis. 39(8), 1095-1103 (2004).
12. Walsh DX, Eamsila C, Sasiprapha T et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multi-drug resistant P. falciparum malaria. J. Infect. Dis. 190(8), 1456-1463 (2004).
13. Nasveld P, Kitchener S. Treatment of acute vivax malaria with tafenoquine. Trans. R. Soc. Trop. Med. Hyg. 99, 2-5 (2005).
14. White NJ, Nosten F, Looareesuwan S et al. Averting a malaria disaster. Lancet 353, 1965-1967 (1999).
15. Omari AA, Gamble C, Garner P. Artemether-lumefantrine for uncomplicated malaria: a systematic review. Trop. Med. Int. Health 9(2), 192-199 (2004).
16. Martensson A, Stromberg J, Sisowath C et al. Efficacy of artesunate plus amodiaquine versus that of artemetherlumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41, 1079-1096 (2005).
17. Centers for Disease Control and Prevention. Health Information for International Travel 2005-2006. Atlanta: US Department of Health and Human Services, Public Health Service (2005).
18. Health Canada: Canadian recommendations for the prevention and treatment of malaria among international travellers. CCDR. 30(S1), 1-62 (2004).
19. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin. Infect. Dis. 33(2), 226-234 (2001).
20. GlaxoSmithKline, Inc. Malarone®. GSK product monograph. 1-36 (2004).
21. Hudson AT, Dickins M, Ginger CD et al. A potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. 17, 427-435 (1991).
22. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33, 704-711 (1999).
23. Looaressuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute, uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54, 62-66 (1996).
24. Berman JD, Nielsen R, Chulay JD et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone®) in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 95, 429-432 (2001).
25. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am. J. Trop. Med. Hyg. 60(5), 831-836 (1999).
26. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43, 1545-1553 (1992).
27. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272, 3961-3966 (1997).
28. Pudney M, Gutteridge W, Zeman A et al. Atovaquone and proguanil hydrochloride: a review of nonclinical studies. J. Travel Med. 6, S8-S12 (1999).
29. Reynolds MG, Roos DS. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J. Biol. Chem. 273, 3461-3469 (1998).
30. Gay F, Bustos D, Traore B. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am. J. Trop. Med. Hyg. 56, 315-317 (1997).
31. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43, 1334-1339 (1999).
32. Helsby NA, Ward SA, Edwards G et al. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br. J. Clin. Pharmacol. 30, 593-598 (1999).
33. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochorme b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44, 2100-2108 (2000).
34. Farnert A, Linkberg J, Gil P et al. Evidence of Plasmodium falciparum malaria resistance to atovaquone and proguanil hydrochloride: case reports. Br. Med. J. 326, 628-629 (2003).
35. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis. 37, 450-451 (2003).
36. Schwoebel B, Alifrangis M, Salanti A, Jelinek T. Different mutations patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar. J. 2, 5 (2003).
37. Kuhn S, Gill J, Kain KC. Atovaquone/proguanil resistant Plasmodium falciparum malaria acquired by a non-immune North American traveler to West Africa. Am. J. Trop. Med. Hyg. 72, 407-409 (2005).
38. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB. Atovaquone/proguanil resistance in Africa: a case report. Scand. J. Infect. Dis. 35, 897-898 (2003).
39. Wichmann O, Muehlberger N, Jelinek T et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J. Infect. Dis. 190, 1541-1546 (2004).
40. Fivelman Q, Butcher G, Adagu I, Wahrurst D, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria [case report]. Malar. J. 1, 1 (2002).
41. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin. Pharmacol. Ther. 61, 518-530 (1997).
42. Gillotin C, Mamet JJP, Veronese L. Lack of pharmacokinetic interaction between atovaquone and proguanil. Eur. J. Clin. Pharmacol. 55, 311-315 (1999).
43. Thapar MM, Ashton M, Lindegardh N et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone®) when taken as chemoprophylaxis. Eur. J. Clin. Pharmacol. 58(1), 19-27 (2002).
44. McGready R, Stepniewska K, Edstein MD et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur. J. Clin. Pharmacol. 59, 545-552 (2003).
45. McGready R, Stepniewska K, Seaton E et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. 59, 553-557 (2003).
46. Lee BL, Sadler B, Goldstein D, Chambers HF. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin. Pharmacol. Ther. 59(1), 14-21 (1996).
47. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin. Pharmacokinet. 30(5), 385-401 (1996).
48. Shanks GD, Gordon DM, Klotz FW et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin. Infect. Dis. 27, 494-499 (1998).
49. Lell B, Luckner D, Ndjave M et al. Randomized placebo-controlled study of atovaquone plus proguanil for malaria in children. Lancet 351, 709-713 (1998).
50. Sukwa TY, Mulenga M, Chisdaka NS et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone® (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am. J. Trop. Med. Hyg. 60, 521-525 (1999).
51. Hogh B, Clarke PD, Camus D et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomized, double-blind study. Malarone International Study Team. Lancet 356, 1888-1894 (2000).
52. Overbosch D, Schilthuis H, Bienzle U et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin. Infect. Dis. 33, 1015-1021 (2001).
53. Faucher JF, Binder R, Missinou MA et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin. Infect. Dis. 35(10), 1147-1154 (2002).
54. Ling J, Baird JK, Fryauff DJ et al. Randomized, double-blind, placebo-controlled evaluation of malarone for prophylaxis of P. vivax and P. falciparum malaria in non-immune transmigrants to Papua. Clin. Infect. Dis. 35, 825-833 (2002).
55. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaqoune and proguanil for Plasmodium falciparum malaria. Lancet 347, 1511-1514 (1996).
56. De Alencar FE, Cerutti C, Durlacher RR et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J. Infect. Dis. 175, 1544-1547 (1997).
57. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 60, 526-532 (1999).
58. Mulenga M, Sukwa TY, Canfield CJ, Hutchinson DB. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin. Ther. 21, 841-852 (1999).
59. Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone/proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in Philippines. J. Infect. Dis. 179, 1587-1590 (1999).
60. Bouchaud O, Monlun E, Muanza K et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am. J. Trop. Med. Hyg. 63, 274-279 (2000).
61. Anabwani G, Canfield CJ, Hutchinson DB. Combination of atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr. Infect. Dis. J. 18, 456-461 (1999).
62. Borrmann S, Faucher JF, Bagaphou T et al. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. J. Infect. Dis. 37, 1441-1447 (2003).
63. van Vugt M, Leolardi E, Phaipun L et al. Treatment of uncomplicated multi-drug resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin. Infect. Dis. 35(12), 1498-1504 (2002).
64. Esamai F, Tenge CN, Ayuo PO, Ong'or WO, Obala A, Jakait B. A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria. J. Trop. Pediatr. 51(1), 17-24 (2005).
65. McGready R, Ashley EA, Moo E et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J. Infect. Dis. 192, 846-853 (2005).
66. Lacy MD, Maguire JD, Barcus MJ et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin. Infect. Dis. 35(9), E92-E95 (2002).
67. Looareesuwan S, Wilairatana P, Glanarongran R et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans. R. Soc. Trop. Med. Hyg. 93(6), 637-640 (1999).
68. Radloff PD, Philipps J, Hutchinson D, Kremsner PG. Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Trans. R. Soc. Trop. Med. Hyg. 90(6), 682 (1996).
69. Peterson E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. J. Travel Med. 10S, S13-S15 (2003).
70. Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J. Travel Med. 10S, S16-S20 (2003).
71. Emberger M, Lechner AM, Zelger B. Stevens-Johnson Syndrome associated with Malarone® antimalarial prophylaxis. Clin. Infect. Dis. 37, E5-E7 (2003).
72. Wongsrichanali C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209-218 (2002).
73. Labbe AC, Patel S, Crandall I, Kain KC. Molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg. Infect. Dis. 9, 33-36 (2003).
74. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone® (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 60(4), 533-541 (1999).
75. Atovaquone/proguanil (Malarone) for malaria. Med. Lett. Drugs Ther. 42(1093), 109-111 (2000).
76. Schlagenhauf P, Tschopp A, Johnson R et al. Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-saharan Africa: multicenter, randomised, double-blind, four-arm study. Br. Med. J. 329, 1078-1081 (2003).